Quantcast

Latest research Stories

2014-07-17 12:30:54

BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant...

2014-07-17 08:33:35

DENVER, July 17, 2014 /PRNewswire/ -- HOSTING, the leading provider of managed cloud services, announced today its inclusion in the Gartner, Inc. 2014 Magic Quadrant for Cloud-Enabled Managed Hosting. This is the third year running that HOSTING has been recognized in the prestigious industry ranking and report from the world's leading information technology research and advisory company. The evaluation criteria are centered on a provider's ability to execute, which includes its service...

2014-07-16 12:28:25

Cognitive function is primary endpoint COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson's disease and other cognitive...

2014-07-16 12:27:23

COSTA MESA, Calif., July 16, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern Californian announced today the successful completion of a large phase I clinical trial. The study protocol required that WCCT Global enroll 180 patients that would stay in their phase I Clinical Pharmacology Unit for an extended period of time. WCCT Global was able to randomize and accommodate all the needed patient cohorts without delays. WCCTG...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 23:07:05

Announcing the Latest Version of the Market-Leading Clinical Conductor CTMS Rochester, NY (PRWEB) July 15, 2014 The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology. With the latest release of Clinical Conductor, the market-leading CTMS again provides unparalleled advances in both features and functionality designed to give users even greater levels of increased efficiency and maximized profits. Most prominently seen in this release are...

2014-07-15 12:29:33

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Autism Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160177/Autism-Global-Clinical-Trials-Review-H1-2014.htmlAutism Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to...

2014-07-15 12:29:11

LONDON and WILMINGTON, N.C. and CARY, N.C., July 15, 2014 /PRNewswire/ -- Chiltern and Ockham, two leading full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services. Chiltern's CEO Jim Esinhart, PhD will be...

2014-07-15 04:22:22

ABERDEEN, Scotland and SINGAPORE, July 15, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-14 23:04:05

Key Questions & Memorable Quotes from #eCongress Toronto, Canada (PRWEB) July 14, 2014 Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.” This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD,...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related